Showing 9751-9760 of 18563 results for "".
- Dr. CI:Labo Presents New Clinical Data on Post-IPL Skincare for Asian Skin at IMCAS Asia 2025https://reachmd.com/news/dr-cilabotm-presents-new-clinical-data-on-post-ipl-skincare-for-asian-skin-at-imcas-asia-2025/2475378/At IMCAS Asia 2025, Dr.CI:LABOTM presented new clinical findings demonstrating the efficacy of two of its skincare products—VC100 Essence Lotion EX and 377VC Radiance Serum—as adjuncts to Intense Pulsed Light (IPL) treatments in Asian patients. The data revealed that VC100 Esse
- FDA Accelerated Approval of Atrasentan: A New Era for IgA Nephropathy Treatmenthttps://reachmd.com/news/fda-accelerated-approval-of-atrasentan-a-new-era-for-iga-nephropathy-treatment/2475057/Atrasentan’s FDA accelerated approval introduces a novel non-steroidal option for patients with IgA nephropathy facing limited effective treatments. The clinical management of IgA nephropathy has long been constrained by reliance on co
- FDA Aligns Infant Formula Standards: Less Protein, More Nutritionhttps://reachmd.com/news/fda-aligns-infant-formula-standards-less-protein-more-nutrition/2475065/As the FDA charts a path toward stricter nutritional benchmarks and safety protocols for infant formulas, pediatricians find themselves at the forefront of translating these changes into improved infant feeding strategies. At a recent
- Urgent Call for Maternal and Infant Measles Vaccinationhttps://reachmd.com/news/urgent-call-for-maternal-and-infant-measles-vaccination/2475063/Measles outbreaks among unvaccinated populations are claiming young lives, as demonstrated by a recent Canadian infant's death, underscoring an urgent need to strengthen vaccination strategies for mothers and infants. A previously heal
- Bridging the Gap: Reinvigorating Interest in Pain Medicine Fellowshipshttps://reachmd.com/news/bridging-the-gap-reinvigorating-interest-in-pain-medicine-fellowships/2475052/Program directors are confronted with a pivotal challenge as anesthesia residents increasingly bypass pain medicine fellowship training</
- Unmasking IL-17: A New Frontier in Spondyloarthritis Managementhttps://reachmd.com/news/unmasking-il-17-a-new-frontier-in-spondyloarthritis-management/2475050/A growing body of evidence reveals that IL-17-driven inflammation in spondyloarthritis remains underrecognized, even as it shapes disease activity and treatment response. Persistent inflammation poses a significant challenge in spondyl
- Innovative Approaches to Combat Antimicrobial Resistance in Gram-Positive Pathogenshttps://reachmd.com/news/innovative-approaches-to-combat-antimicrobial-resistance-in-gram-positive-pathogens/2474991/The rise in antimicrobial resistance necessitates innovative treatment approaches for resistant gram-positive pathogens. Infectious disease specialists confronting persistent cases of drug-resistant gram-positive pathogens, including m
- Enhancing Preterm Infant Nutrition: Emerging Insights into Maternal Diet and Milk Compositionhttps://reachmd.com/news/enhancing-preterm-infant-nutrition-emerging-insights-into-maternal-diet-and-milk-composition/2475027/Optimizing preterm infant nutrition through targeted maternal diet represents a pivotal yet underutilized strategy to enhance the nutrient density of human milk, addressing the unique vulnerabilities of preterm infants. Neonatologists
- Emerging Integrations in Cardiovascular Risk: The Role of Inflammatory and Metabolic Indiceshttps://reachmd.com/news/emerging-integrations-in-cardiovascular-risk-the-role-of-inflammatory-and-metabolic-indices/2475037/As the burden of metabolic syndrome rises, clinicians are recognizing that systemic inflammatory and metabolic markers are not mere bystanders but powerful predictors of cardiovascular outcomes, demanding a reevaluation of risk stratification
- Redefining Coronary Artery Disease Intervention: Novel Approaches in Pharmacology, Surgery, and Imaginghttps://reachmd.com/news/redefining-coronary-artery-disease-intervention-novel-approaches-in-pharmacology-surgery-and-imaging/2475034/Clinicians have long grappled with the narrow therapeutic window of antiplatelet therapy in coronary artery disease, where the protection against thrombosis with aspirin comes at the cost of residual ischemic events and potent alternatives ra